CRDL Cardiol Therapeutics Inc - Ordinary Shares - Class A

Cardiol Therapeutics (NASDAQ:CRDL Get Free Report) and BioAtla (NASDAQ:BCAB Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast...

Cantor Fitzgerald reissued their overweight rating on shares of Cardiol Therapeutics (NASDAQ:CRDL Free Report) in a research note issued to investors on Monday morning, Benzinga reports. Cantor Fitzgerald currently has a $3.00 price objective on the stock. Cantor Fitzgerald also issued estimates for...

Cardiol Therapeutics Inc. (NASDAQ:CRDL Free Report) Cantor Fitzgerald increased their FY2023 earnings per share estimates for Cardiol Therapeutics in a research note issued on Monday, August 14th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings of...

Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart...

Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of ...

Cardiol Therapeutics Inc. (NASDAQ:CRDL Get Free Report) shot up 0.9% on Friday . The company traded as high as $1.22 and last traded at $1.17. 407,324 shares were traded during mid-day trading, an increase of 209% from the average session volume of 131,738 shares. The stock had previously ...